IVD Antibody Development Services for EGFR Marker

As a world-leading antibody service provider, Creative Biolabs is professional in discovery and development of in vitro diagnostic (IVD) antibodies. Our years of experience, vast expertise, and advanced platforms make us confident in offering the most comprehensive IVD antibody development services against various markers of lung cancer. Our professional team will help you with the best quality and cost-effective services to make your project a success.

General Description of EGFR

As a member of the erbB family of closely related receptor tyrosine kinases, Epidermal growth factor receptor (EGFR) comprise of erbB1 (also known as EGFR), erbB2 (HER2), erbB3, and erbB4. EGFR is a transmembrane glycoprotein, including an extracellular epidermal growth factor binding domain, an intracellular tyrosine kinase domain, a transmembrane portion and regulatory domains, which regulates signaling pathways to affect cellular proliferation migration, survival, adhesion, and differentiation. While EGFR binds to its ligand (e.g. EGF, TGF-α), autophosphorylation can be triggered by intrinsic tyrosine/kinase activity and then resulting in several signal transduction cascades. The key signaling pathways cover the PI3K/Akt, and signal transducer, activator of transcription (STAT) factors and Raf1-extracellular signal-regulated kinase. The biology of cell proliferation or cell maintenance by inhibition of apoptosis depends on these pathways.

Fig.1 EGFR and its mutations in cancers.¹

Assessment of EGFR Marker Abnormalities in Lung Cancer

According to the current reports, EGFR is a key mediator of tumor progression, which is associated with increased or inappropriate signaling in non-small-cell lung cancer (NSCLC). Mutations in EGFR have been found related to some lung cancers. Both EGFR mutation and gene amplification status may be crucial in determining which tumors will respond to tyrosine kinase inhibitors (TKI). As a result, activating mutations in EGFR are important markers of response to TKI therapy in NSCLC. Moreover, EGFR and KRAS mutational status, ALK rearrangements, and MET immunohistochemistry are important biomarkers and of current or imminent value in lung cancer. With using the mutation-specific mAbs against EGFR, IHC is a promising method for detecting EGFR mutations to assess the EGFR Marker abnormalities in NSCLC patients.

IVD Antibody Development Service for EGFR Marker

IVD antibodies are extensively applied in immunodiagnostic kits for disease diagnosis, therapeutic monitoring, and guiding the use of targeted therapies. Immunodiagnostic kits based on various formats can be used to detect the disease marker, such as immunonephelometry, immunohistochemistry, immunofluorescence, and sandwich ELISA. Creative Biolabs offers customized IVD antibody development services targeting EGFR as well as IVD immunoassay development services of various formats. We have accumulated years of experience and expertise, which allows us to offer the best quality services to our global clients.

Reference

1. Sigismund, Sara, Daniele Avanzato, and Letizia Lanzetti. "Emerging functions of the EGFR in cancer." Molecular oncology 12.1 (2018): 3-20.

For Research Use Only.